Daniel Castellano

8.8K posts

Daniel Castellano

Daniel Castellano

@cdanicas

Medical Oncologist. Hospital Univ. 12 de Octubre. Madrid. UCM. Head GU Unit. Executive Member @GUARDconsortitum

Katılım Ocak 2013
1.7K Takip Edilen3.8K Takipçiler
Daniel Castellano retweetledi
GUARD Consortium
GUARD Consortium@GuardConsortium·
#InsightClínico 🔬 En cáncer renal metastásico, combinaciones IO + IO o IO + TKI continúan consolidándose como estándar en primera línea La selección del tratamiento debe considerar: ✔ Riesgo pronóstico ✔ Perfil de toxicidad ✔ Comorbilidades ✔ Objetivos terapéuticos del paciente La personalización es clave. #RenalCellCarcinoma #mRCC #Oncology @DrFelixGuerrero @cdanicas @dralvaropinto @drenriquegrande @fcounago @docjavip @BerUrologia @DrJaVallejo @Maroto5Pablo @nachoduranm @RodriguezAntona @AnaPlatabello1
GUARD Consortium tweet media
Español
0
3
5
184
Daniel Castellano retweetledi
Gil Morgan, MD
Gil Morgan, MD@weoncologists·
🌐 Gran noticia: El 6.º Coloquio @OncoAlert 🚨 ya está DISPONIBLE EN TU IDIOMA! 🇪🇸🇮🇳🇵🇹🇮🇹🇫🇷🇺🇦🇯🇵🇲🇽🇸🇦🇷🇺 1⃣8⃣Idiomas hablados y subtitulados disponibles ENCUENTRALOS AQUI👉 oncoalert360.com/multi-language… @GuardConsortium @cdanicas @drenriquegrande @DrJaVallejo @dralvaropinto @mjuanfi81
OncoAlert@OncoAlert

🌐 Big news: The 6th OncoAlert 🚨Colloquium is NOW AVAILABLE IN YOUR LANGUAGE!! 🇪🇸🇮🇳🇵🇹🇮🇹🇫🇷🇺🇦🇯🇵🇲🇽🇸🇦🇷🇺and many more SPOKEN & WITH CAPTIONS in 1⃣8⃣Languages ALL VIDEOS HERE 👇👇oncoalert360.com/multi-language… Top oncology experts. Global reach. Zero barriers. Watch the 50-sec video to learn how #BreastCancer @hoperugo🇺🇸 @matteolambe🇮🇹 @Icro_Meattini🇮🇹 Dr. Roberto Salgado 🇧🇪 @ErikaHamilton9 🇺🇸 @DrSGraff 🇺🇸 @itrisabel🇪🇸 @ESSOnews @ElisaAgostinett 🇧🇪 @RebeccaDSing 🇸🇬 @LazarPo31787807 🇷🇸 #LungCancer @GlopesMd🇺🇸 @jillfeldman4 🇺🇸 @UmbertoMalapel1 🇮🇹 @BRicciutiMD 🇺🇸 @UOzkerim 🇹🇷 @DrMirallas🇺🇸 GU Oncology @brian_rini 🇺🇸 @declangmurphy 🇦🇺 @KidneyCancer🇺🇸 @salvolarosa @Silke_Gillessen🇨🇭 @RenuEapen🇦🇺 @nataliagandur 🇦🇷 @seanmcbride 🇺🇸 @jAvallejo 🇪🇸@GuardConsortium GI Oncology @BenWestphalen 🇩🇪 @graokane 🇮🇪 @GIMedOnc🇺🇸 @NiuSanford 🇺🇸 @ARosen380 🇺🇸 @Erman_Akkus 🇹🇷 @realbowtiedoc 🇺🇸 GynOnc @NicoloBizzarri 🇮🇹Vanda Salutari 🇮🇹 @AStrojnaMD 🇩🇪Alejandra Martinez 🇫🇷 @CoquardRay 🇫🇷Christina Fotopoulou 🇬🇧Giorgia Garganesse 🇮🇹 @ChargariC 🇫🇷 @PaulJiL H&N🇬🇧 @DrJasonWestin Lymphoma🇺🇸 @FadiHaddad_MD Leukemia🇺🇸 @Abdallah81MD Multiple Myeloma🇺🇸 @NassifElise Sarcoma 🇺🇸 @DrBetofMDPhD Melanoma🇺🇸 Our Partners @ESGO_society @ESSOnews @CancerCareMASCC @SIOGorg Our Collaborators @APCCC_Lugano @gu_onc @Uromigos and more and more to come.......

Español
0
7
10
542
Daniel Castellano retweetledi
Advanced Prostate Cancer Consensus Conference
Advanced Prostate Cancer Consensus Conference@APCCC_Lugano·
Genomic Profiling in Localized Prostate Cancer: Associations With Biochemical Recurrence and Response to Salvage Radiotherapy onlinelibrary.wiley.com/doi/10.1111/ca… Comprehensive genomic profiling in localized #ProstateCancer identified alterations in six genes🧬 (PTEN, BRCA2, POLD1, ERBB3, MYC, SETD2) associated with biochemical recurrence and worse recurrence-free survival after prostatectomy. Alteration-positive patients showed higher stage and recurrence rates. BRCA2, especially with SETD2 co-alteration, predicted poorer outcomes. These findings suggest genomic profiling may refine risk stratification, though further validation is needed before guiding management in localized disease. @OncoAlert 🚨 @Silke_Gillessen @AOmlin @weoncologists
Advanced Prostate Cancer Consensus Conference tweet media
English
0
10
19
1.1K
Daniel Castellano retweetledi
GUARD Consortium
GUARD Consortium@GuardConsortium·
La investigación colaborativa es el motor del avance en tumores genitourinarios. En GUARD Consortium conectamos especialistas para impulsar estudios independientes, formación y generación de evidencia clínica. 👉 Síguenos también en LinkedIn y forma parte de la comunidad científica. #GUARDConsortium #ClinicalResearch #OncologyNetwork @DrFelixGuerrero @cdanicas @dralvaropinto @drenriquegrande @fcounago @docjavip @BerUrologia @DrJaVallejo @Maroto5Pablo @nachoduranm @RodriguezAntona @AnaPlatabello1
GUARD Consortium tweet media
Español
0
5
8
300
Daniel Castellano retweetledi
Cancer Cell
Cancer Cell@Cancer_Cell·
The cellular orchestra of CAR T success dlvr.it/TRX8rM
Cancer Cell tweet media
English
0
25
89
5.6K
Daniel Castellano retweetledi
GUARD Consortium
GUARD Consortium@GuardConsortium·
Desde #GU26, la Dra. @mjuanfi81 presenta una nueva cápsula informativa sobre el ensayo fase 3 KEYNOTE-B15/EV-304 en cáncer de vejiga músculo-invasivo candidato a cisplatino. La combinación perioperatoria de enfortumab vedotin + pembrolizumab redujo el riesgo de recurrencia o progresión en un 47% y aumentó la tasa de respuesta patológica completa (56% vs 32,5%). Resultados que podrían redefinir el estándar perioperatorio en MIBC ⤵️
OncoAlert@OncoAlert

COLLEAGUES AT #EAU26 Our friends from @GuardConsortium 🇪🇸Deliver another Great Informational Capsule, this time direct from #GU26 🇺🇸 We are proud to introduce our Colleague @mjuanfi81 Discussing the Presentation of: KEYNOTE-B15/EV 304 The phase 3 KEYNOTE-B15 trial evaluated perioperative enfortumab vedotin plus pembrolizumab versus standard cisplatin-based chemotherapy in 808 patients with muscle-invasive #BladderCancer eligible for cisplatin. The combination reduced recurrence or progression risk by 47% and improved pathologic complete response rates (56% vs 32.5%). Although higher-grade toxicities occurred, results suggest this regimen may improve survival and represent a potential new perioperative standard, warranting further comparative investigation. buff.ly/LIBgTVi @cdanicas @dralvaropinto @drenriquegrande @nachoduranm @DrJaVallejo @abraocantoMD @docjavip @AlvarezMa89031 @DrFelixGuerrero @BerUrologia @AnaPlatabello1 @AlvarezMa89031 @scocmem @OncBrothers @Helena_de_Palma @F_lopez_campos @Dav_Lorente @EurUrolOncol @tompowles1

Español
0
6
9
1.3K
Daniel Castellano retweetledi
OncoAlert
OncoAlert@OncoAlert·
A reminder that #APCCC26 🇨🇭is coming in Late April and is OPEN TO EVERYONE, not just the Panel members and 👉️ REGISTER HERE: buff.ly/XpCWPdR 🚨 Enjoy 20% off when registering for both APCCC & IPCS 2026 Awarm invite to the Advanced Prostate Cancer Consensus Conference #APCCC26 in Lugano🇨🇭 Event Details: 📍 Palazzo Congressi, Lugano, Switzerland 🎟️ Register here 🎓 Credits requests: SGU – SSU, SSMO, SRO, SGMN In an era of rapid innovation and expanding treatment options for advanced #ProstateCancer , APCCC provides a vital forum for clinicians and researchers to address complex clinical questions where high-level evidence is limited. Over two days, the world’s leading experts will engage in high-level presentations, debates, and discussions to clarify and conceptualize the current landscape of care, with a focus on areas of controversy or uncertainty. The insights and consensus developed during the meeting are later published in European Urology, helping shape global standards. Creating new opportunities for younger investigators & the next generation of leaders in advanced prostate cancer! @Silke_Gillessen & @AOmlin @fabioturco92 @Prof_IanD @drjefstathiou @Prof_Nick_James @ChrisSweens1 @BertrandTOMBAL @ZilliThomas @neerajaiims @bjartell @PBlanchardMD @BourlonMaite @Albert0Briganti @cdanicas @Ecastromarcos @mdesantis234 @nachoduranm @drlouiseemmett @stefanofanti4 @fontev1 @Nicola_Fossati @marty_gleave @ProfKHerrmann @DrMHofman @BarbaraJereczek @ravikanesvaran @FacsRaja @LoebStacy @quimmateo @DrRanaMcKay @amerseburger @CaPsurvivorship @declangmurphy @DrPaulNguyen @WilliamOhMD @piet_ost @DrSpratticus @cnsternberg @DrYukselUrun Ping @nataliagandur @OncoAlert 🚨
English
0
8
13
816
Daniel Castellano retweetledi
Julian Chavarriaga
Julian Chavarriaga@chavarriagaj·
#EAU26 Dr. von Amsberg on when to introduce PARPi: mHSPC or should we wait until mCRPC? 🧬 BRCA1/2-mutated mHSPC behaves differently. • Poorer prognosis • Less benefit from ARPIs/docetaxel • PARP inhibitor combinations show the strongest rPFS signal (emerging OS) in BRCA1/2 💡~1 in 4 men never receive another line of therapy → effective treatments may need to move earlier, not later. @uroweb @UroToday
Julian Chavarriaga tweet media
English
2
28
52
2.8K
Daniel Castellano retweetledi
UroToday.com
UroToday.com@urotoday·
Circulating and urine tumor DNA dynamics predict minimal residual disease and recurrence risk in locally advanced #UTUC: CURATE-UTUC – A multicenter prospective longitudinal cohort study. Presentation by Jiwei Huang. #EAU26 written coverage by @zklaassen_md > bit.ly/473DONU @Uroweb
UroToday.com tweet mediaUroToday.com tweet mediaUroToday.com tweet media
English
1
8
12
720
Daniel Castellano retweetledi
@DocMeetings - Urology
@DocMeetings - Urology@docmeetings·
PRostate cancer guidelines 2026 update. Digital rectal exam NOW no more recommended for Asymptomatic men SO NO MORE FOR Screening Important for standing and for early diagnosis for SYMPTOMS only @Uroweb
@DocMeetings - Urology tweet media@DocMeetings - Urology tweet media
English
4
91
215
32.1K
Daniel Castellano retweetledi
Giulio Francolini
Giulio Francolini@GiulioFrancoli1·
🚀 Largest prospective SABR cohort in inoperable RCC. Pooled FASTRACK trials show 98% local control at 5 years, excellent CSS, low ≥G3 toxicity and no late safety signals. A durable, non‑invasive, kidney‑sparing option—now poised for randomized comparison vs surgery. #EAU26
Giulio Francolini tweet mediaGiulio Francolini tweet mediaGiulio Francolini tweet mediaGiulio Francolini tweet media
English
3
31
88
7.8K
Daniel Castellano retweetledi
Cancer Cell
Cancer Cell@Cancer_Cell·
Macrophages: Targets for next-generation cancer immunotherapy dlvr.it/TRT4tD
Cancer Cell tweet media
English
2
75
245
18.4K
Daniel Castellano retweetledi
Michael Hofman
Michael Hofman@DrMHofman·
Proud moment and HUGE news from #EAU26: #PRIMARY2 shows PSMA PET/CT can safely halve prostate biopsies in men with equivocal MRI, avoiding biopsy in 49% without missing cancer. uroweb.org/news/scan-that…
English
8
71
247
18.2K
Daniel Castellano retweetledi
Advanced Prostate Cancer Consensus Conference
Advanced Prostate Cancer Consensus Conference@APCCC_Lugano·
New prostate cancer risk groups by PSMA-PET (PPP3): an international, retrospective, registry-based cohort study thelancet.com/journals/lanon… In an international registry study of 11,154 patients, investigators developed PPP3 nomograms integrating clinical features and PSMA-PET PROMISE metrics to predict 3-, 5-, and 7-year overall survival in #ProstateCancer Developed and validated across 35 global sites, ✅ Models demonstrated strong discrimination (C-index ~0.83–0.84). ✅PPP3 performed as well as or better than existing clinical risk scores, supporting PSMA-PET–based risk stratification for guidelines, clinical decision-making, and trial design. @CalaisJeremie @DrMHofman @thomashopemd @drlouiseemmett @DrAGafita @ProfKHerrmann @ProfHadaschik @Dr_K_Rahbar @bjartell @OncoAlert 🚨 @silkegillessen @AOmlin @weoncologists #EAU26
Advanced Prostate Cancer Consensus Conference tweet media
English
0
23
52
2.9K
Daniel Castellano retweetledi
GUARD Consortium
GUARD Consortium@GuardConsortium·
🧠 Insight clínico En #OncologíaGU, el reto ya no es solo tratar, sino estratificar mejor. Biomarcadores, perfil molecular y correcta secuenciación terapéutica están redefiniendo la práctica clínica. La medicina de precisión ya es presente. #OncologíaGU #PrecisionOncology @DrFelixGuerrero @cdanicas @dralvaropinto @drenriquegrande @fcounago @docjavip @BerUrologia @DrJaVallejo @Maroto5Pablo @nachoduranm @RodriguezAntona @AnaPlatabello1
GUARD Consortium tweet media
Español
0
4
9
428
Daniel Castellano retweetledi
Tom Powles
Tom Powles@tompowles1·
sac-TMT+pembro in 1st line UC shows ⬆️⬆️ efficacy (Fudan Uni 🇨🇳) . It’s a TROP2/TOPO1 ADC but efficacy looks different from SG or D-DXD @scocmem In 1st line UC it has 68% ORR , 1yr PFS & 80% 12 month OS. 60% TRAEs,13% tox discontinuations. This mono and combo requires further exploration. @OncoAlert
Tom Powles tweet mediaTom Powles tweet mediaTom Powles tweet mediaTom Powles tweet media
English
5
43
112
12.6K

Keşfet

@DrFelixGuerrero @dralvaropinto @drenriquegrande @fcounago @docjavip @BerUrologia @DrJaVallejo @Maroto5Pablo